Editors' ChoiceCancer

Double trouble for CML

+ See all authors and affiliations

Science Translational Medicine  05 Apr 2017:
Vol. 9, Issue 384, e2773
DOI: 10.1126/scitranslmed.aan2773

You are currently viewing the abstract.

View Full Text

Abstract

Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.

View Full Text

Related Content